Wanbury to launch new iron supplement C-RED & API Ketamine

Wanbury Limited, a pharmaceutical company listed on both the NSE and BSE, announced today it will launch two new products this month: a branded formulation called Wanbury C-RED and an active pharmaceutical ingredient (API) – Ketamine Hydrochloride.

The shares of Wanbury Limited were trading at ₹266.01 up by ₹25.09 or 10.41 per cent on the NSE today at 2.18 pm.

Wanbury C-RED is a liposomal iron supplement targeting the gynaecology segment, specifically designed to improve haemoglobin levels, particularly during pregnancy. The company claims this formulation prevents gastric irritation and constipation while ensuring better absorption compared to existing iron salts in the market.

The Ketamine Hydrochloride API, developed through Wanbury’s in-house R&D team, complies with major pharmacopeia standards, including USP and EP. The company stated that Ketamine has an annual demand exceeding 200 tonnes for both human and veterinary markets and is primarily used to induce sleep before and during surgeries.

Wanbury will begin supplying Ketamine this month, starting with exports to European markets.

Established in 1988, Wanbury Limited operates two FDA- and EUGMP-approved facilities in Tanuku (Andhra Pradesh) and Patalganga (Maharashtra). The company exports APIs to over 50 countries and maintains a pan-India presence in the formulation market with products across therapeutic categories, including cough and cold solutions, gynaecology, orthopaedics and gastrointestinal treatments.